ProCE Banner Activity

Expert Commentary on Key Updates in Managing IgA Nephropathy

Clinical Thought

Recent therapeutic advances in treating IgA nephropathy have greatly expanded nephrologist’s armamentarium and improved patient outcomes as shown in clinical trials. Learn strategies for incorporating targeted-release budesonide, endothelin receptor antagonists, sodium–glucose cotransporter 2 inhibitors, and iptacopan to treat patients with IgA nephropathy.

Released: August 26, 2024

Expiration: August 25, 2025

Share

Faculty

Pietro Canetta

Pietro Canetta, MD, MS

Associate Professor of Medicine
Division of Nephrology
Columbia University Irving Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC in collaboration with American Kidney Fund

ProCE Banner

Supporters

Supported by educational grants from Novartis Pharmaceuticals Corporation and Otsuka America Pharmaceuticals.

Novartis Pharmaceuticals Corporation

Otsuka America Pharmaceuticals

Partners

American Kidney Fund

ProCE Banner

Disclosure

Primary Author

Pietro Canetta, MD, MS

Associate Professor of Medicine
Division of Nephrology
Columbia University Irving Medical Center
New York, New York

Pietro Canetta, MD, MS: consultant/advisor/speaker: Novartis, Takeda; independent contractor: Otsuka.